|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.
|
30575147 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used mouse SCC cells derived from tumors harboring a Kras<sup>G12D</sup> activation mutation and Smad4 deletion in keratin 15-positive stem cells and a human oral SCC cell line, FaDu, which has <i>NRAS</i> amplification and <i>SMAD4</i> deletion.
|
31189369 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disulfiram inhibits epithelial-mesenchymal transition through TGFβ-ERK-Snail pathway independently of Smad4 to decrease oral squamous cell carcinoma metastasis.
|
31118804 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, SMAD4 loss is a potential biomarker in SCCs that should be further studied for its values in prognostic and therapeutic predictions.
|
31140647 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among TGF-β/Smad signaling, only TGF-βRII or Smad4 deletion in mouse epithelium causes spontaneous SCC in the mouse model, highlighting the critical roles of TGF-βRII and Smad4 in tumor suppression.
|
29206939 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, Smad4-mediated signaling is required to initiate epithelial carcinogenesis subsequent to <i>TGFBR2</i> deletion in FSP1<sup>+</sup> fibroblasts.<b>Implications:</b> These findings reveal a complex cross-talk between epithelial cells and the stroma, wherein Smad4 is required to elicit squamous cell carcinomas in the forestomach of mice with <i>TGFBR2</i>-deficient stromal cells.<i></i>.
|
29934328 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of TGF‑β1 and SMAD4 proteins was elevated in cervical squamous carcinoma and cervical adenocarcinoma tissues.
|
27748903 |
2016 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we established a mouse model by injecting tumor cells derived from primary SCCs harboring KrasG12D mutation and Smad4 deletion into wild-type (wt) or CD8-/- recipients.
|
27835902 |
2016 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We developed a mouse model of SCC by targeting two frequent genetic mutations in human SCCs, oncogene Kras(G12D) activation and Smad4 deletion, to mouse keratin 15-expressing (K15+) stem cells.
|
23999427 |
2013 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For Smad4, statistical difference was observed only in SCC samples (p=0.014), but not in BCC and AK samples (p=0.173 and 0.314, respectively).
|
22301403 |
2012 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We show equal detection of a homozygous loss of SMAD4 at the exon-level in the SW480 cell line and gene-specific alterations in the split tumor samples. aCGH application to a set of archival FFPE samples of skin squamous cell carcinomas detected a novel hemizygous deletion in INPP5A on 10q26.3.
|
19875416 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FaDu, an invasive, Smad4-deficient SCC, also allowed 2kΔN transactivation by transfected Smad2 in the presence of endogenous IKKα.
|
21170261 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the incidence of HGF-positive human SCC was high in cases with Smad2 loss and lower when Smad4 was also lost.
|
20852387 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we found that Smad2 and Smad4, but not Smad3, were frequently lost in human SCCs.
|
18618014 |
2008 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
|
16478646 |
2007 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Aberrant expression of Smad4, a TGF-beta signaling molecule, in oral squamous cell carcinoma.
|
17023741 |
2006 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
|
15867212 |
2005 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanisms of resistance to TGF-beta caused by modulation of cell cycle regulators and/or inactivation of components of the TGF-beta signaling transduction pathway such as C-myc and Smad4 have been demonstrated in human pancreatic cancer and squamous cell carcinoma cell lines.
|
10810347 |
2000 |